PharmaCyte Biotech Inc Net Asset Quality Index
PharmaCyte Biotech Inc net asset quality index. PharmaCyte Biotech Inc (PMCB) has a Net Asset Quality Index of 74.8% as of April 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $46.75 Million minus total liabilities of $11.77 Million yields net assets of $34.98 Million. A higher index indicates a stronger, lower-leverage balance sheet. See PharmaCyte Biotech Inc shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of PharmaCyte Biotech Inc (2004–2026)
Net asset quality index of PharmaCyte Biotech Inc from 2004 to 2026. This chart shows how PharmaCyte Biotech Inc's Net Asset Quality Index has evolved across 23 annual periods from 2004 to 2026. As of April 2026, the index stands at 74.8%, representing net assets of $34.98 Million against total assets of $46.75 Million USD. Check PMCB capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
PharmaCyte Biotech Inc Net Asset Quality Index by Year (2004–2026)
PharmaCyte Biotech Inc net asset quality index by year from 2004 to 2026. The table below presents the year-by-year Net Asset Quality Index for PharmaCyte Biotech Inc from 2004 to 2026, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see PMCB company net worth.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2026 | 74.8% | $34.98 Million | $46.75 Million | $11.77 Million | ▼ -19.2 pp |
| 2025 | 94.1% | $51.89 Million | $55.17 Million | $3.28 Million | ▲ +28.1 pp |
| 2024 | 66.0% | $39.51 Million | $59.90 Million | $20.39 Million | ▼ -33.2 pp |
| 2023 | 99.2% | $72.69 Million | $73.28 Million | $586.58K | ▼ 0.0 pp |
| 2022 | 99.2% | $89.92 Million | $90.62 Million | $704.37K | ▲ +9.0 pp |
| 2021 | 90.2% | $6.68 Million | $7.40 Million | $724.78K | ▲ +7.7 pp |
| 2020 | 82.5% | $5.09 Million | $6.17 Million | $1.08 Million | ▼ -4.6 pp |
| 2019 | 87.2% | $5.04 Million | $5.78 Million | $742.85K | ▼ -2.8 pp |
| 2018 | 90.0% | $5.77 Million | $6.41 Million | $644.17K | ▼ -3.4 pp |
| 2017 | 93.3% | $8.09 Million | $8.67 Million | $580.25K | ▲ +2.2 pp |
| 2016 | 91.1% | $6.52 Million | $7.16 Million | $637.64K | ▲ +16.4 pp |
| 2015 | 74.7% | $5.94 Million | $7.95 Million | $2.01 Million | ▼ -21.3 pp |
| 2014 | 96.0% | $8.94 Million | $9.32 Million | $373.67K | ▲ +128.0 pp |
| 2013 | -32.0% | $-921.46K | $2.88 Million | $3.80 Million | ▲ +49.4 pp |
| 2012 | -81.4% | $-1.70 Million | $2.09 Million | $3.79 Million | ▲ +138.6 pp |
| 2011 | -220.1% | $-2.73 Million | $1.24 Million | $3.97 Million | ▼ -57.8 pp |
| 2010 | -162.3% | $-1.95 Million | $1.20 Million | $3.15 Million | ▼ -214.0 pp |
| 2009 | 51.7% | $3.12 Million | $6.04 Million | $2.92 Million | ▼ -45.9 pp |
| 2008 | 97.6% | $7.44 Million | $7.62 Million | $180.56K | ▲ +0.3 pp |
| 2007 | 97.3% | $4.29 Million | $4.41 Million | $118.81K | ▲ +11.4 pp |
| 2006 | 85.9% | $4.41 Million | $5.14 Million | $723.89K | ▲ +470.9 pp |
| 2005 | -385.0% | $-1.30 Million | $336.36K | $1.63 Million | ▼ -297.7 pp |
| 2004 | -87.3% | $-153.43K | $175.71K | $329.13K | — |